Announcements Trials
Browse Landscape

Status

Recruiting 2Active not recruiting 2Withdrawn 1Unknown 1Terminated 1Completed 1

Sponsor Class

OTHER 1

Study Type

Observational 1

Sponsor

Cancer Type

Lymphoid 1Dermatologic 1

Conditions

Prostatic Neoplasms 6Leukemia, Myeloid, Acute 4Colorectal Neoplasms 4Carcinoma, Non-Small-Cell Lung 4Uterine Cervical Neoplasms 3Sarcoma 3Pancreatic Neoplasms 3Multiple Myeloma 3Lung Neoplasms 3Breast Neoplasms 3Triple Negative Breast Neoplasms 2Stomach Neoplasms 2Rectal Neoplasms 2Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2Ovarian Neoplasms 2Neoplasm Metastasis 2Myelodysplastic Syndromes 2Melanoma 2Lymphoma 2Leukemia, Biphenotypic, Acute 2Colonic Neoplasms 2Carcinoma, Intraductal, Noninfiltrating 2Burkitt Lymphoma 2Uterine Cervical Dysplasia 1Tongue Neoplasms 1Thrombocytosis 1Thrombocytopenia 1Squamous Cell Carcinoma of Head and Neck 1Salivary Gland Neoplasms 1Pruritus 1

Interventions

Peripheral Blood Stem Cell Transplantation 4Cyclophosphamide 4fludarabine phosphate 3Vorinostat 3Cytarabine 3Whole-Body Irradiation 2Tacrolimus 2Pentetic Acid 2Mycophenolic Acid 2Methotrexate 2Bortezomib 2sargramostim 1pembrolizumab 1fludarabine 1ethanolamine oleate 1denileukin diftitox 1cemiplimab 1Vincristine 1Trimethoprim, Sulfamethoxazole Drug Combination 1Trimethoprim 1Transplantation 1Thiotepa 1Therapeutics 1Surveys and Questionnaires 1Sulfamethoxazole 1Sodium Chloride 1Saline Solution, Hypertonic 1Saline Solution 1Radiotherapy 1Psychiatric Rehabilitation 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Mycosis Fungoides × Biopsy × Clear all
NCT01801670 2015-01-27

Impact of Vorinostat on Pruritus Signaling Pathways - Merck Study

Boston University

Withdrawn
DermatologicLymphoid

Mycosis Fungoides, Pruritus, Lymphoma, T-Cell, Cutaneous

Data powered by HemOnc (CC BY 4.0) Colophon âš¡